Further, Tatton-Brown et al. reported that no patients in their study possessed a DNMT3A mutation affecting the Arg882 residue, the target of over 50% of somatic DNMT3A mutations found in AML, suggesting that de novo mutations found in overgrowth syndromes differ from the common somatic DNMT3A mutations [154]. This evidence concerns the gene DNMT3A and overgrowth syndrome.